These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 29959799

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L, Chen ZH, Liu D, Cheng YG, Luo XP.
    Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
    [Abstract] [Full Text] [Related]

  • 3. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J.
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [Abstract] [Full Text] [Related]

  • 4. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C.
    Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
    [Abstract] [Full Text] [Related]

  • 5. PEGylated Recombinant Human Growth Hormone Jintrolong® Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.
    Wu W, Zhou J, Wu C, Zhou Q, Li X, Zhang Y, Zuo C, Yin J, Hou L, Wang S, Gao H, Luo T, Jin L, Zhong E, Wang Y, Luo X.
    Front Endocrinol (Lausanne); 2022 Aug; 13():821588. PubMed ID: 35909512
    [Abstract] [Full Text] [Related]

  • 6. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile.
    Rasmussen MH, Jensen L, Anderson TW, Klitgaard T, Madsen J.
    Clin Endocrinol (Oxf); 2010 Dec; 73(6):769-76. PubMed ID: 20718773
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation.
    Liedert B, Forssmann U, Wolna P, Golob M, Kovar A.
    BMC Clin Pharmacol; 2010 Oct 20; 10():14. PubMed ID: 20961422
    [Abstract] [Full Text] [Related]

  • 8. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M.
    J Clin Endocrinol Metab; 2014 Oct 20; 99(10):E1819-29. PubMed ID: 25013997
    [Abstract] [Full Text] [Related]

  • 9. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
    Søndergaard E, Klose M, Hansen M, Hansen BS, Andersen M, Feldt-Rasmussen U, Laursen T, Rasmussen MH, Christiansen JS.
    J Clin Endocrinol Metab; 2011 Mar 20; 96(3):681-8. PubMed ID: 21177789
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency.
    Du H, Wu D, Yi P, Bai X, Luo Y, Yang H, Chen S, Pan H, Zhu H.
    J Pediatr Endocrinol Metab; 2022 Apr 26; 35(4):511-517. PubMed ID: 35245011
    [Abstract] [Full Text] [Related]

  • 13. Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.
    Lewis AL, Jordan F, Patel T, Jeffery K, King G, Savage M, Shalet S, Illum L.
    J Clin Endocrinol Metab; 2015 Nov 26; 100(11):4364-71. PubMed ID: 26425883
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Pharmacokinetics of rhGH decorated by polyethylene glycol in rat in vivo].
    Jiang L, Cai YM, Zeng Y, Huang J, Chen ZM.
    Yao Xue Xue Bao; 2009 May 26; 44(5):506-9. PubMed ID: 19618727
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: a pharmacokinetic, safety and tolerability study.
    Jen J, LaBadie RR, Liang Y, Crownover PH, Gao X, Hey-Hadavi JH.
    Growth Horm IGF Res; 2013 Aug 26; 23(4):114-9. PubMed ID: 23651793
    [Abstract] [Full Text] [Related]

  • 20. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH, Janukonyté J, Klose M, Marina D, Tanvig M, Nielsen LF, Höybye C, Andersen M, Feldt-Rasmussen U, Christiansen JS.
    J Clin Endocrinol Metab; 2016 Mar 26; 101(3):988-98. PubMed ID: 26727076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.